homepage-top-section

Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis.

The studies indicated that the Depakine has induced disabilities in about 15,000 to 30,000 children whose mothers took the drug valproate during pregnancy. The drug, which has been

The phase III COVACTA study of tocilizumab did not reach its primary endpoint of improved clinical status in hospitalised adult patients with severe Covid-19 associated pneumonia. Roche’s trial

Both companies have decided to advance their BNT162b2 vaccine candidate into the phase 2/3 study at a 30µg dose level in a two-dose regimen after an extensive assessment

Tecartus, earlier known as KTE-X19, is claimed to be the first and only approved chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory MCL. Tecartus,

Novartis has said that it will provide medicines to governments, NGOs and other institutional customers in up to 79 eligible nations until a vaccine or curative treatment is

The company, which has administered the first doses in healthy human volunteers, is also planning to initiate a phase 2/3 study this October. The phase I clinical trial

The two of the firms’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine programme, including BNT162b1 and BNT162b2, are being developed to treat SARS-CoV-2. BioNTech chief medical

The company is evaluating an agonistic (immunostimulatory) humanised monoclonal antibody, dubbed CPI-006, which is said to show a potential new approach to immunotherapy of infectious diseases and cancer.